PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America

NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera

PharmaEssentia Initiates Phase 3b Trial of ropeginterferon alfa-2b-njft Investigating New Dosing Regimen for Patients with Polycythemia Vera (PV)

PharmaEssentia Corporation Announces Closing of Global Depositary Receipt Offering, Generating US$462.7M to Support Growth Plans and Pipeline Development

PharmaEssentia Initiates Phase 2b Trial of ropeginterferon alfa-2b-njft for Essential Thrombocythemia (ET) in North America

Clinical Review of Ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera

PharmaEssentia Establishes a New Research and Development Facility in the Boston Area

PharmaEssentia to Present at the 41st Annual J.P. Morgan Healthcare Conference

New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey

Presentations on Ropeginterferon Alfa-2b During ASH Annual Meeting Highlight Momentum in the Care of Polycythemia Vera (PV)